News Channels

01 Dec 2018 Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
01 Dec 2018 AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer
30 Nov 2018 Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
30 Nov 2018 Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
30 Nov 2018 MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
30 Nov 2018 Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program
30 Nov 2018 Shire Receives European Approval for TAKHZYRO (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema
30 Nov 2018 Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
30 Nov 2018 Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
29 Nov 2018 Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
29 Nov 2018 TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
29 Nov 2018 European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriat
29 Nov 2018 Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to
29 Nov 2018 FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
29 Nov 2018 Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
29 Nov 2018 XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
29 Nov 2018 Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
28 Nov 2018 Cold Genesys Announces Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA® (pembrolizumab) in Bladder Cancer
28 Nov 2018 HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement to Discover and Prioritize Novel Immunogenic, Tumor-Specific Cryptic Antigens
28 Nov 2018 Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up